Leroy V - Search Results

1

Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effects of dose and duration.

Poynard T, Leroy V, Cohard M, Thevenot T, Mathurin P, Opolon P, Zarski JP. Poynard T, et al. Among authors: leroy v. Hepatology. 1996 Oct;24(4):778-89. doi: 10.1002/hep.510240405. Hepatology. 1996. PMID: 8855176

2

Treatment of chronic hepatitis C by interferon for longer duration than six months.

Poynard T, Leroy V, Mathurin P, Cohard M, Opolon P, Zarski JP. Poynard T, et al. Among authors: leroy v. Dig Dis Sci. 1996 Dec;41(12 Suppl):99S-102S. doi: 10.1007/BF02087883. Dig Dis Sci. 1996. PMID: 9011484 Clinical Trial.

3

[Should hepatitis C be screened? Risk factors of transmission of hepatitis C virus].

Zarski JP, Leroy V. Zarski JP, et al. Among authors: leroy v. Gastroenterol Clin Biol. 1997;21(1 Pt 2):S4-10. Gastroenterol Clin Biol. 1997. PMID: 9161509 Review. French. No abstract available.

4

Tenoxicam, a non-steroid anti-inflammatory drug, is unable to increase the response rate in patients with chronic hepatitis C treated by alpha interferon.

Zarski JP, Maynard-Muet M, Chousterman S, Baud M, Barnoud R, Abergel A, Bacq Y, Combis JM, Causse X, Tran A, Oberti F, Minello A, Bresson-Hadni S, Bailly F, Raabe JJ, Leroy V, Hamici L, Hicham T, Girardin MF. Zarski JP, et al. Among authors: leroy v. Hepatology. 1998 Mar;27(3):862-7. doi: 10.1002/hep.510270332. Hepatology. 1998. PMID: 9500719 Clinical Trial.

5

Role of anti-interferon antibodies in breakthrough occurrence during alpha 2a and 2b therapy in patients with chronic hepatitis C.

Leroy V, Baud M, de Traversay C, Maynard-Muet M, Lebon P, Zarski JP. Leroy V, et al. J Hepatol. 1998 Mar;28(3):375-81. doi: 10.1016/s0168-8278(98)80309-7. J Hepatol. 1998. PMID: 9551673

6

[Value of high-dose interferon-alpha in chronic viral hepatitis C patients non-responder to a 1st treatment. Pilot study prospective and randomized trial].

Rolachon A, Kézachian G, Causse X, Baud M, Leroy V, Maynard-Muet M, Pasquier D, Zarski JP. Rolachon A, et al. Among authors: leroy v. Gastroenterol Clin Biol. 1997;21(12):924-8. Gastroenterol Clin Biol. 1997. PMID: 9587555 Free article. Clinical Trial. French.

7

Prevalence and significance of anticardiolipin, anti-beta2 glycoprotein I and anti-prothrombin antibodies in chronic hepatitis C.

Leroy V, Arvieux J, Jacob MC, Maynard-Muet M, Baud M, Zarski JP. Leroy V, et al. Br J Haematol. 1998 Jun;101(3):468-74. doi: 10.1046/j.1365-2141.1998.00722.x. Br J Haematol. 1998. PMID: 9633888 Free article.

8

[Acute viral hepatitis A, B, C, D and E: epidemiology, etiology, diagnosis, course, prevention].

Zarski JP, Leroy V, Maynard-Muet M. Zarski JP, et al. Among authors: leroy v. Rev Prat. 1998 Sep 15;48(14):1609-14. Rev Prat. 1998. PMID: 9814059 Review. French. No abstract available.

9

[What is the status of hepatitis C virus infection in France?].

Leroy V, Zarski JP. Leroy V, et al. Gastroenterol Clin Biol. 1999 Mar;23(3):349-51. Gastroenterol Clin Biol. 1999. PMID: 10384337 Free article. French. No abstract available.

10

Counselling patients with hepatitis C.

Zarski JP, Leroy V. Zarski JP, et al. Among authors: leroy v. J Hepatol. 1999;31 Suppl 1:136-40. doi: 10.1016/s0168-8278(99)80390-0. J Hepatol. 1999. PMID: 10622576 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

607 results

Search Page